Thiamine deficiency as a possible cofactor causing cognitive dysfunction in a patient with end-stage gastric cancer .


Journal

International journal of clinical pharmacology and therapeutics
ISSN: 0946-1965
Titre abrégé: Int J Clin Pharmacol Ther
Pays: Germany
ID NLM: 9423309

Informations de publication

Date de publication:
Aug 2019
Historique:
accepted: 17 07 2019
pubmed: 25 6 2019
medline: 6 8 2019
entrez: 25 6 2019
Statut: ppublish

Résumé

We describe a case of a patient treated for cognitive dysfunction (CD) with suspected thiamine deficiency (TD). A 74-year-old man with gastric cancer presented with grade 3 diarrhea and grade 1 anorexia. He had been receiving trastuzumab plus tegafur (a chemotherapeutic fluorouracil prodrug), gimeracil, and oteracil (S-1) and oxaliplatin. On admission, cognitive function was assessed with the Hasegawa's Dementia Scale (HDS-R) because he had impaired short-term memory. His thiamine levels increased from 22 to 109 ng/mL after administration of 75 mg of thiamine. Furthermore, the patient's HDS-R score improved from 9 to 22, and cognitive and memory functions improved. TD should be considered in older CD patients receiving oral chemotherapy agents including fluorouracil.

Identifiants

pubmed: 31232276
pii: 185272
doi: 10.5414/CP203384
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

416-419

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH